Skip to main content
COGT
NASDAQ Life Sciences

Cogent Q3 Loss Widens to $111M as Three FDA Decisions Loom

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$29.21
Mkt Cap
$5.133B
52W Low
$13.78
52W High
$43.73
52W Position info
112% above low
Off High info
33% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

COGT has more than doubled off its 52-week low of $13.78.

Summary

Cogent's Q3 net loss widened to $111.4 million from $96.4 million in Q2, with operating expenses of $117.2 million as it funds the SUMMIT, PEAK and APEX trials and builds out commercial readiness. The cash pile of $791.1 million is roughly flat versus the $792.3 million reported at Q2 and management says it funds operations into late 2028. The real story is the approval calendar: bezuclastinib could get an FDA nod in GIST by Nov. 30, 2026, in NonAdvSM by Dec. 30, 2026, and in AdvSM by June 29, 2027 — three shots on goal inside about 18 months. The loss itself is the expected cost of that ramp, not a surprise, so the stock reaction should hinge on the GIST decision due within weeks.

At the time of this announcement, COGT was trading at $29.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $13.78 to $43.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

COGT - Latest Insights

COGT
Nov 05, 2026, 4:28 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $29.58 info
Change: +$0.370 (+1%) info
Market Cap: $5.133B info
COGT
Sep 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.50
Real-time Price: $29.58 info
Change: -$3.92 (-12%) info
Market Cap: $5.133B info
COGT
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.53
Real-time Price: $29.58 info
Change: -$11.95 (-29%) info
Market Cap: $5.133B info
COGT
Aug 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.55
Real-time Price: $29.58 info
Change: -$10.97 (-27%) info
Market Cap: $5.133B info
COGT
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $38.60
Real-time Price: $29.58 info
Change: -$9.02 (-23%) info
Market Cap: $5.133B info